Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development

Summary

The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF

Timeline

Start

2019-01-03

Primary completion

2022-12-01

Completion

2022-12-01

Publications

• Pose E, Jimenez C, Zaccherini G, Campion D, Piano S, Uschner FE, de Wit K, Roux O, Gananandan K, Laleman W, Sole C, Alonso S, Cuyas B, Ariza X, Juanola A, Ma AT, Napoleone L, Gratacos-Gines J, Tonon M, Pompili E, Sanchez-Delgado J, Allegretti AS, Morales-Ruiz M, Carol M, Perez-Guasch M, Fabrellas N, Pich J, Martell C, Joyera M, Domenech G, Rios J, Torres F, Serra-Burriel M, Hernaez R, Sola E, Graupera I, Watson H, Soriano G, Banares R, Mookerjee RP, Francoz C, Beuers U, Trebicka J, Angeli P, Alessandria C, Caraceni P, Vargas VM, Abraldes JG, Kamath PS, Gines P; LIVERHOPE Consortium. Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial. JAMA. 2025 Mar 11;333(10):864-874. doi: 10.1001/jama.2024.27441.
• Marrache MK, Rockey DC. Statins for treatment of chronic liver disease. Curr Opin Gastroenterol. 2021 May 1;37(3):200-207. doi: 10.1097/MOG.0000000000000716.

Drugs

Indications